The future of cancer treatment is targeted and precise. And the future is now. Non-carrier-added lutetium-177 (or Lu-177) is the true power behind smarter cancer therapies. It’s a radioactive agent that, when paired with a cancer-seeking molecule, fights disease by bonding to and killing cancer cells.
Lutetium-177 works together with cancer-seeking molecules. The drug smartly delivers the isotope to cancer and its metastases. The isotope emits short-range radiation that damages, or even potentially kills, the cancer without affecting nearby tissue. We are proud that our product is commercial and being used by customers today in Lu-177 therapies globally.
Our n.c.a. Lu-177 is produced in accordance with current Good Manufacturing Practice and meets or exceeds all European pharmacopeia monograph for lutetium. We submitted a Drug Master File to the U.S. FDA in 2022. We are working to rapidly expand our production capabilities, including aiming to bring our large-scale facility, Cassiopeia, online in 2023.
We’re working on becoming the only vertically integrated manufacturer of lutetium-177 in the world. By enriching the raw feedstock material – ytterbium-176 – needed for production, producing neutrons to irradiate the Yb-176, and separating the Lu-177 from the Yb-176 to meet customer specifications, we aim to eliminate our dependency on a nuclear reactor for our Lu-177 production.
Enter your email below to download our medical isotope information sheets.
We stand apart from other fusion companies because we have commercialized fusion today and we are scaling our technology. During each of our four phases, we’re perfecting core competencies needed for commercially viable fusion, producing useful products, building shareholder value, and reinvesting in future growth.
Join us and be part of the solution.